Pilot Study: Comparison of the efficacy of artemisinin plus piperaquine (Artequick), artesunate plus amodiaquine (Coarsucam) and artesunate plus azithromycin for the treatment of Plasmodium falciparum malaria in Vietnam
Australian Army Malaria Institute
180 participants
May 27, 2008
Interventional
Conditions
Summary
Over 80 countries worldwide use artemisinin-based combination therapy (ACT) as first-line treatment of Plasmodium falciparum malaria. Debate continues as to the most effective ACT and how they will be deployed. Which ACT is the best combination therapy for first-line treatment in Vietnam has not been adequately studied. In the present study, we propose to investigate the efficacy and tolerability of three ACTs (artemisinin plus piperaquine, artesunate plus amodiaquine and artesunate plus azithromycin) in central Vietnam.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Malaria patients will be administered either Artequick (2.5 mg/kg artemisinin and 15 mg/kg piperaquine daily) for 2 days, Coarsucam (4 mg/kg artesunate plus 10 mg/kg amodiaquine daily) for 3 days or 4 mg/kg artesunate plus 30 mg/kg azithromycin daily for 3 days. The mode of administration is oral dosing.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000816257